Rogers Corporation ROG

New real-world results for Vabysmo in nAMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals1-3Advanced AI-enabled analysis of imaging confirms rapid and meaningful anatomical drying supporting Vabysmo as a standard-of-care therapy in routine clinical care4,5With more than 5,000 patients enrolled, VOYAGER is the largest, prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical p

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus1By targeting resistance to endocrine treatments, the giredestrant combination seeks to delay disease progression and improve overall patient outcomes1The FDA has set a PDUFA goal date for giredestrant in early-stage breast cancer of 30 November 2026 and in advanced disease of 18 December 2026 Basel, 1 Oct

Rogers Stock Jumps 11% as Investor Day Sets $1. 5 Billion 2030 Revenue TargetRogers Corporation (ROG:NYSE) stock climbed 10.

Shares of engineered materials manufacturer Rogers (NYSE:ROG) jumped 17% in the morning session after it hosted an Investor Day, where management laid out strategy and multi-year financial targets through 2030. According to the company’s Investor Day presentation, President and CEO Ali El-Haj and CFO Laura Russell outlined growth priorities tied to AI data centers, vehicle electrification, and capital allocation, along with financial objectives through 2030. Management targeted about a 13% reven

CHANDLER, Ariz., September 30, 2026--Rogers Corporation (NYSE: ROG) ("Rogers") today presented its strategy to accelerate growth, expand profitability and increase earnings through 2030 at the Company’s 2026 Investor Day.

CHANDLER, Ariz., September 30, 2026--Rogers Corporation (NYSE:ROG) ("Rogers") will host an Investor Day, Wednesday, September 30, 2026, in New York City.

Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability1Fenebrutinib became the first investigational medicine in more than a decade to slow disability progression in a Phase III PPMS trial (FENtrepid), with numerical benefit vs Ocrevus2Fenebrutinib is designed to address two drivers of MS – acute inflammation causing relapses and chronic brain inflammation driving disability progression1

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.

Rogers has delivered a sharp move over the past year, which puts today’s valuation squarely in focus. With the share price well above where it started the period, the question now is how much of that climb is supported by the company’s earnings power. The stock has returned 72.6% over the past year, which raises the stakes on whether current buyers are paying a full price for its earnings profile. The business depends heavily on its ability to convert specialized materials demand into steady...

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potentialSefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage1IgAN is a progressive kidney disease that is typically diagnosed in young adults and up to 50% of people progress to kidney failure within 20 years, requiring

Roche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche’s Annual General Meeting on March 9, 2027. Roche Chairman Severin Schwan: “I am pleased that we have been able to propose Christophe Weber for election to the Board of Directors. Christophe’s intimate knowledge of the healthcare industry and his broad leadership experience will further strengthen

At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic controlIn patients with poor baseline glycemic control (HbA1c >8.5%), enicepatide 24 mg led to an HbA1c reduction of 4.13% at 48 weeksBy week 48, 90% of patients in the 24 mg enicepatide arm met the T2D glycemic target of ≤6.5% HbA1c, while 62% achieved normoglycemia (HbA1c < 5.7%)At the highest 24 mg dose, enicepatide achieved a mean weight loss

By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for nAMD1-3Susvimo helps people with nAMD maintain their vision with as few as two treatments per year1-3Data from the Phase III Archway study showed that Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections2nAMD is a leading cause of vision loss in adults

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Ocrevus addresses a critical need in paediatric neurology as the first high- efficacy anti-CD20 treatment option for people with MS as young as 10 years old In the Phase III OPERETTA 2 study, Ocrevus demonstrated non-inferiority in relapse control and superiority over fingolimod in suppressing brain lesions1Safety in children and adolescents was aligned with the established safety profile of Ocrevus across more than 525,000 adult patients globally1 Basel, 18 September 2026 - Roche (SIX: RO, ROP;

The center will be a hub for Roche and Genentech, bringing together expertise in Cardiovascular, Renal and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and developmentIt will expand Roche’s and Genentech’s presence in Boston, reflecting a long-term commitment to one of the world’s leading life sciences hubsThis is part of Roche and Genentech’s USD 50 billion investment in US manufacturing and R&D, building on recent investments and manufacturin

Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatmentData reinforce the potential of this Lunsumio-based regimen to improve clinical outcomes, while offering a tolerable safety profile, simple dosing schedule and outpatient administration Data will be submitted to health auth

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.